Impedimed Ltd - Asset Resilience Ratio
Impedimed Ltd (IPD) has an Asset Resilience Ratio of 52.04% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Impedimed Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Impedimed Ltd's Asset Resilience Ratio has changed over time. See IPD total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Impedimed Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IPD stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$21.68 Million | 52.04% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$21.68 Million | 52.04% |
Asset Resilience Insights
- Very High Liquidity: Impedimed Ltd maintains exceptional liquid asset reserves at 52.04% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Impedimed Ltd Industry Peers by Asset Resilience Ratio
Compare Impedimed Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vitrolife AB
ST:VITR |
Medical Devices | 7.27% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 8.60% |
|
Lumos Diagnostics Holdings Ltd
AU:LDX |
Medical Devices | 9.40% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
|
Ok Biotech Co Ltd
TW:4155 |
Medical Devices | 0.32% |
|
Promimic AB
ST:PRO |
Medical Devices | 8.62% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Annual Asset Resilience Ratio for Impedimed Ltd (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Impedimed Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 52.04% | AU$21.68 Million ≈ $15.34 Million |
AU$41.66 Million ≈ $29.48 Million |
+12.90pp |
| 2024-06-30 | 39.14% | AU$18.39 Million ≈ $13.01 Million |
AU$46.99 Million ≈ $33.25 Million |
+19.42pp |
| 2023-06-30 | 19.71% | AU$13.55 Million ≈ $9.59 Million |
AU$68.74 Million ≈ $48.64 Million |
-33.59pp |
| 2022-06-30 | 53.30% | AU$31.29 Million ≈ $22.14 Million |
AU$58.70 Million ≈ $41.53 Million |
+19.68pp |
| 2021-06-30 | 33.62% | AU$11.50 Million ≈ $8.14 Million |
AU$34.20 Million ≈ $24.20 Million |
+7.07pp |
| 2020-06-30 | 26.55% | AU$8.78 Million ≈ $6.21 Million |
AU$33.06 Million ≈ $23.39 Million |
-9.61pp |
| 2019-06-30 | 36.16% | AU$8.16 Million ≈ $5.78 Million |
AU$22.58 Million ≈ $15.98 Million |
-31.92pp |
| 2018-06-30 | 68.08% | AU$28.30 Million ≈ $20.02 Million |
AU$41.57 Million ≈ $29.41 Million |
-5.30pp |
| 2017-06-30 | 73.38% | AU$47.22 Million ≈ $33.41 Million |
AU$64.34 Million ≈ $45.53 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$90.57 Million ≈ $64.08 Million |
-- |
| 2012-06-30 | 0.16% | AU$31.00K ≈ $21.93K |
AU$19.61 Million ≈ $13.88 Million |
+0.02pp |
| 2011-06-30 | 0.14% | AU$31.00K ≈ $21.93K |
AU$22.80 Million ≈ $16.14 Million |
-0.08pp |
| 2008-06-30 | 0.21% | AU$31.00K ≈ $21.93K |
AU$14.52 Million ≈ $10.27 Million |
-0.47pp |
| 2007-06-30 | 0.68% | AU$148.00K ≈ $104.72K |
AU$21.79 Million ≈ $15.42 Million |
-- |
About Impedimed Ltd
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue compositi… Read more